Equities analysts forecast that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will post earnings of ($1.44) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings. The highest EPS estimate is ($1.38) and the lowest is ($1.50). Aerie Pharmaceuticals reported earnings of ($0.72) per share during the same quarter last year, which would suggest a negative year over year growth rate of 100%. The firm is expected to issue its next earnings report on Tuesday, March 6th.
On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($3.42) per share for the current financial year, with EPS estimates ranging from ($3.49) to ($3.34). For the next fiscal year, analysts forecast that the business will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.38) to ($1.82). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Aerie Pharmaceuticals.
A number of equities research analysts have recently issued reports on AERI shares. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 price target for the company in a research report on Monday, July 24th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 1st. Finally, HC Wainwright set a $69.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $71.43.
Aerie Pharmaceuticals (NASDAQ:AERI) traded down $1.00 during mid-day trading on Wednesday, hitting $58.70. The stock had a trading volume of 378,123 shares, compared to its average volume of 638,111. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 1-year low of $35.20 and a 1-year high of $66.25.
WARNING: “Zacks: Analysts Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Announce -$1.44 Earnings Per Share” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/18/zacks-analysts-anticipate-aerie-pharmaceuticals-inc-aeri-to-announce-1-44-earnings-per-share.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.